K
Krishna Pramanik
Researcher at National Institute of Technology, Rourkela
Publications - 108
Citations - 5482
Krishna Pramanik is an academic researcher from National Institute of Technology, Rourkela. The author has contributed to research in topics: Fibroin & Bone tissue. The author has an hindex of 33, co-authored 105 publications receiving 4389 citations. Previous affiliations of Krishna Pramanik include Department of Biotechnology & Techno India.
Papers
More filters
Journal ArticleDOI
Properties and use of jatropha curcas oil and diesel fuel blends in compression ignition engine
TL;DR: In this paper, the effect of temperature on the viscosity of biodiesel and jatropha oil was studied and the performance of a single cylinder C.I. engine using blends of varying proportions of Jatropha curcas oil and diesel was evaluated.
Journal ArticleDOI
Antimicrobial activity of iron oxide nanoparticle upon modulation of nanoparticle-bacteria interface
Manoranjan Arakha,Sweta Pal,Devyani Samantarrai,Tapan Kumar Panigrahi,Bairagi C. Mallick,Krishna Pramanik,Bibekanand Mallick,Suman Jha +7 more
TL;DR: The data indicated that the chitosan coating of IONP result in interface that enhances ROS production, hence the antimicrobial activity.
Journal ArticleDOI
Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
TL;DR: Citation Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors.
Journal ArticleDOI
Polymers in Mucoadhesive Drug-Delivery Systems: A Brief Note
TL;DR: The current review provides a good insight on mucocoadhesive polymers, the phenomenon of mucoadhesion and the factors which have the ability to affect the muco adhesion properties of a polymer.
Journal ArticleDOI
Calcium alginate-carboxymethyl cellulose beads for colon-targeted drug delivery
Tarun Agarwal,S. N. Gautham Hari Narayana,Kunal Pal,Krishna Pramanik,Supratim Giri,Indranil Banerjee +5 more
TL;DR: Cytotoxicity data, nuclear condensation-fragmentation and apoptosis analysis together confirmed the therapeutic potential of the CA-CMC formulations and they can be used for colon-specific drug delivery.